| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;78:1152-1160
© 2004 The Society of Thoracic Surgeons
a Departments of Thoracic and Cardiovascular Surgery, Houston, TX, USA
b Radiology, Houston, TX, USA
c Gastrointestinal Oncology, Houston, TX, USA
d GI Medicine and Nutrition, Houston, TX, USA
e Radiation Oncology, Houston, TX, USA
f Nuclear Medicine, Houston, TX, USA
g Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
Accepted for publication April 12, 2004.
* Address reprint requests to Dr Swisher, Department of Thoracic and Cardiovascular Surgery, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 445, Houston, TX 77030, USA
sswisher{at}mdanderson.org
Presented at the Fortieth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 26–28, 2004.
BACKGROUND: This study evaluates the utility of positron emission tomography (PET), endoscopic ultrasonography (EUS), and computed tomographic (CT) scans to predict pathologic response and survival following preoperative chemoradiation (CRT) in esophageal cancer.
METHODS: One hundred three sequential patients with locoregionally advanced esophageal cancer, who were treated with CRT and esophageal resection between May 2001 and November 2003 at the University of Texas M.D. Anderson Cancer Center, were retrospectively reviewed. PET, EUS, and CT were performed before (pre) or after (post) CRT and before surgical resection. PET standardized uptake value (SUV) was defined as maximal uptake in primary tumor.
RESULTS: Most patients were male (91 [88%]) with adenocarcinoma (90 [87%]). Pretreatment clinical stages were: IIA (42 [41%]), IIB (5 [5%]), III (50 [49%]), and IVA (6 [6%]). At the time of surgery, 58 patients (56%) had a pathologic response to CRT (
10% viable cells). Post-CRT measurements that correlated with pathologic response were: CT esophageal wall thickness (13.3 vs 15.3 mm, p = 0.04), EUS mass size (0.7 vs 1.7 cm, p = 0.01) and PET SUV (3.1 vs 5.8, p = 0.01). Post-CRT PET SUV equal to or greater than 4 had the highest accuracy for pathologic response (76%). Univariate and multivariate Cox regression analysis demonstrated that a post-CRT PET SUV equal to or greater than 4 was an independent predictor of survival (HR, 3.5, p = 0.04).
CONCLUSIONS: The FDG-PET SUV is the most accurate noninvasive test to predict long-term survival after preoperative CRT and before surgical resection. Post-CRT FDG-PET cannot, however, rule out residual microscopic disease so esophagectomy should remain a therapeutic option even if the post-CRT imaging modalities are normal.
This article has been cited by other articles:
|
|
 |
|
  F. P. Worden, B. Kumar, J. S. Lee, G. T. Wolf, K. G. Cordell, J. M.G. Taylor, S. G. Urba, A. Eisbruch, T. N. Teknos, D. B. Chepeha, et al. Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number J. Clin. Oncol., July 1, 2008; 26(19): 3138 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-B. D'Journo, P. Michelet, L. Dahan, C. Doddoli, J.-F. Seitz, R. Giudicelli, P. A. Fuentes, and P. A. Thomas Indications and outcome of salvage surgery for oesophageal cancer Eur. J. Cardiothorac. Surg., June 1, 2008; 33(6): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Bruzzi, R. F. Munden, M. T. Truong, E. M. Marom, B. S. Sabloff, G. W. Gladish, R. B. Iyer, T.-S. Pan, H. A. Macapinlac, and J. J. Erasmus PET/CT of Esophageal Cancer: Its Role in Clinical Management RadioGraphics, November 1, 2007; 27(6): 1635 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kleinberg and A. A. Forastiere Chemoradiation in the Management of Esophageal Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4110 - 4117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Port, P. C. Lee, R. J. Korst, Y. Liss, D. Meherally, P. Christos, M. Mazumdar, and N. K. Altorki Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Meyers, R. J. Downey, P. A. Decker, R. J. Keenan, B. A. Siegel, R. J. Cerfolio, R. J. Landreneau, C. E. Reed, D. M. Balfe, F. Dehdashti, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 738 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Korst, A. L. Kansler, J. L. Port, P. C. Lee, Y. Kerem, and N. K. Altorki Downstaging of T or N Predicts Long-Term Survival After Preoperative Chemotherapy and Radical Resection for Esophageal Carcinoma Ann. Thorac. Surg., August 1, 2006; 82(2): 480 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Wieder, A. J. Beer, F. Lordick, K. Ott, M. Fischer, E. J. Rummeny, S. Ziegler, J. R. Siewer, M. Schwaiger, and W. A. Weber Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagogastric Junction J. Nucl. Med., December 1, 2005; 46(12): 2029 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
